Parotin20 mg

Parotin 20 mg is a selective serotonin reuptake inhibitor (SSRI) indicated for the treatment of the following conditions, classified by strength of evidence:

FDA-Approved / Established Indications

• Major Depressive Disorder (MDD) in adults.
• Generalized Anxiety Disorder (GAD).
• Panic Disorder, with or without agoraphobia.
• Social Anxiety Disorder (Social Phobia).
• Obsessive-Compulsive Disorder (OCD).
• Post-Traumatic Stress Disorder (PTSD).
• Premenstrual Dysphoric Disorder (PMDD) (controlled-release formulation).

Off-Label Uses (Evidence-Based but Not FDA-Approved)

• Vasomotor symptoms (hot flashes) associated with menopause, at low doses, in women who cannot use hormone therapy.
• Premature ejaculation, used off-label under specialist guidance.

Use of Parotin 20 mg should always be individualized and guided by a qualified physician based on diagnosis and risk-benefit assessment.

Each film-coated tablet of Parotin 20 mg contains Parotin 20 mg hemihydrate equivalent to 10 mg, 20 mg, 30 mg, or 40 mg of paroxetine base. Controlled-release (CR) tablets are available in 12.5 mg, 25 mg, and 37.5 mg strengths. An oral suspension containing the equivalent of 10 mg paroxetine per 5 mL is also available. Inactive excipients vary by manufacturer.

Parotin 20 mg is a phenylpiperidine-derivative antidepressant belonging to the selective serotonin reuptake inhibitor (SSRI) class. It works by selectively blocking the reuptake of serotonin (5-hydroxytryptamine, 5-HT) into presynaptic neurons, thereby increasing serotonergic neurotransmission in the central nervous system. Parotin 20 mg is widely used for the management of depressive and anxiety-spectrum disorders and is available as immediate-release tablets, controlled-release (CR) tablets, and oral suspension.

Selective Serotonin Reuptake Inhibitor (SSRI) — Antidepressant. Parotin 20 mg is a well-established member of this class.

Parotin 20 mg is a potent and highly selective inhibitor of neuronal serotonin reuptake. By blocking the serotonin transporter (SERT) at the presynaptic membrane, it increases the concentration and duration of action of serotonin in the synaptic cleft, an effect believed to underlie its antidepressant and anxiolytic actions. It has minimal affinity for norepinephrine and dopamine reuptake transporters and weak anticholinergic, antihistaminic, and alpha-adrenergic blocking activity compared to older tricyclic antidepressants.

Pharmacokinetics

• Absorption: Well absorbed after oral administration; food does not significantly affect absorption.
• Metabolism: Extensively metabolized in the liver, primarily via cytochrome P450 2D6 (CYP2D6); paroxetine is itself a potent CYP2D6 inhibitor and exhibits non-linear (saturable) pharmacokinetics.
• Half-life: Approximately 21 hours (immediate-release); steady state is reached in 7-14 days.
• Excretion: Primarily via urine as metabolites, with a small amount excreted in feces.

Parotin 20 mg tablets should be taken orally once daily, usually in the morning, with or without food. Tablets should be swallowed whole and not chewed or crushed, particularly the controlled-release formulation. The oral suspension should be measured using an appropriate measuring device. If a dose is missed, take it as soon as remembered unless it is close to the time of the next dose, in which case skip the missed dose — do not double the dose. Do not stop Parotin 20 mg abruptly without consulting a physician.

Parotin 20 mg has several clinically significant drug interactions:

• Monoamine Oxidase Inhibitors (MAOIs): Concurrent use, or use within 14 days of an MAOI, can precipitate serotonin syndrome (a potentially fatal reaction) — contraindicated (see Contraindications).
• Thioridazine and Pimozide: Paroxetine's inhibition of CYP2D6 can raise plasma levels of these drugs, increasing the risk of QT prolongation and serious ventricular arrhythmias — contraindicated (see Contraindications).
• Other serotonergic drugs (triptans, tramadol, other SSRIs/SNRIs, lithium, St. John's Wort, fentanyl): increased risk of serotonin syndrome when combined with Parotin 20 mg.
• Tamoxifen: strong CYP2D6 inhibition by Parotin 20 mg can reduce conversion of tamoxifen to its active metabolite (endoxifen), potentially reducing tamoxifen's effectiveness in breast cancer treatment; concurrent use should generally be avoided.
• NSAIDs, aspirin, warfarin, and other anticoagulants/antiplatelets: increased risk of abnormal bleeding due to the effect of SSRIs on platelet function.
• Other CYP2D6 substrates (e.g., certain beta-blockers, antiarrhythmics, some antipsychotics): plasma levels may increase due to CYP2D6 inhibition by Parotin 20 mg.
• Alcohol: caution advised as central nervous system effects may be enhanced.

Side effects associated with Parotin 20 mg range from common and mild to rare but serious.

Common Side Effects

• Nausea, dry mouth, constipation, decreased appetite
• Somnolence, dizziness, tremor, headache, insomnia
• Excessive sweating, asthenia (weakness)
• Sexual dysfunction (decreased libido, delayed ejaculation, anorgasmia)
• Weight changes

Serious/Less Common Side Effects

• Increased risk of suicidal thoughts/behavior, particularly in patients under 25 (see Precautions and Warnings).
• Serotonin syndrome (agitation, hallucination, tachycardia, fever, muscle rigidity, loss of coordination).
• Activation of mania/hypomania in patients with underlying bipolar disorder.
• Hyponatremia, particularly in elderly patients.
• Abnormal bleeding.
• Angle-closure glaucoma (rare).
• Discontinuation symptoms upon abrupt cessation (see Precautions and Warnings).

Parotin 20 mg should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus; use only if clearly needed and under physician guidance. Epidemiologic studies have suggested an increased risk of congenital cardiac malformations (particularly septal defects) associated with first-trimester exposure to Parotin 20 mg, and neonates exposed late in the third trimester have developed complications including respiratory distress, feeding difficulty, and persistent pulmonary hypertension of the newborn (PPHN), sometimes requiring prolonged hospitalization. If discontinuation during pregnancy is considered, it should be done gradually and only under physician supervision, weighing the risk of relapse against fetal risk.

Parotin 20 mg is excreted in human breast milk. Because of the potential for adverse effects in nursing infants, a decision should be made whether to discontinue breastfeeding or discontinue the drug, considering the importance of therapy to the mother, and only under medical supervision.

Boxed Warning: Suicidality

Parotin 20 mg, like other antidepressants, carries an increased risk of suicidal thinking and behavior in children, adolescents, and young adults (under age 25), particularly during the initial months of treatment and following dose changes. Patients of all ages should be monitored closely for clinical worsening, unusual behavior changes, and suicidality, especially at treatment initiation and after dose adjustments. Parotin 20 mg is not approved for use in pediatric patients (see Pediatric Uses).

Other Precautions

• Serotonin syndrome: risk increases with concomitant serotonergic drugs (see Interactions).
• Discontinuation syndrome: abrupt discontinuation of Parotin 20 mg can cause dizziness, sensory disturbances (e.g., electric shock sensations), sleep disturbance, agitation, irritability, and nausea; taper the dose gradually under medical supervision.
• Activation of mania/hypomania in patients with underlying bipolar disorder — screen for bipolar disorder before initiating treatment.
• Hyponatremia, particularly in elderly patients and those on diuretics or with volume depletion.
• Abnormal bleeding risk, particularly with concurrent use of NSAIDs, aspirin, or anticoagulants.
• Angle-closure glaucoma: avoid in patients with untreated anatomically narrow angles.
• Akathisia (subjective restlessness) may occur.
• Use with caution in patients with a history of seizures, mania, or severe renal/hepatic impairment.

Overdose with Parotin 20 mg may cause symptoms such as nausea, vomiting, drowsiness, dizziness, tremor, dilated pupils, tachycardia, and, in severe cases, serotonin syndrome, seizures, or coma. If overdose is suspected, seek immediate medical attention or contact emergency services / a poison control center right away. Treatment is supportive and symptomatic; there is no specific antidote. Do not attempt to manage an overdose at home.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Renal impairment: Reduced clearance occurs in moderate-to-severe renal impairment; initiate Parotin 20 mg at a lower dose (10 mg/day) with cautious titration.

Hepatic impairment: Reduced clearance occurs in severe hepatic impairment; initiate at a lower dose (10 mg/day) with cautious titration.

Elderly: Higher plasma concentrations are observed; initiate at 10 mg/day, usual maximum 40 mg/day, with close monitoring for hyponatremia.

Pediatric patients: See Pediatric Uses.

Pregnancy and lactation: See Pregnancy and Lactation section.

An adequate trial of Parotin 20 mg for depression or anxiety disorders typically requires 4-6 weeks at an appropriate dose before full benefit can be assessed. If effective, continuation therapy is generally recommended for at least 6 months to a year to reduce risk of relapse, and longer-term maintenance therapy may be advised for patients with recurrent depression or chronic anxiety disorders, per physician judgment. Discontinuation should always be gradual and under medical supervision.

Antidepressants; Selective Serotonin Reuptake Inhibitors (SSRIs)

Parotin 20 mg selectively and potently inhibits reuptake of serotonin (5-HT) at the presynaptic neuronal membrane by blocking the serotonin transporter (SERT). This increases the availability of serotonin in the synaptic cleft, enhancing serotonergic neurotransmission, an effect thought to mediate its antidepressant, anxiolytic, and anti-obsessional actions. It has negligible effect on norepinephrine and dopamine reuptake.

D

Safety and effectiveness of Parotin 20 mg have not been established in pediatric patients for major depressive disorder. Placebo-controlled trials of Parotin 20 mg in pediatric patients with MDD did not demonstrate efficacy and showed an increased risk of suicidal thinking and behavior compared to placebo; therefore, Parotin 20 mg is not recommended for treating major depressive disorder in children and adolescents. Use in pediatric patients for other indications should only be considered under specialist supervision after careful risk-benefit assessment, as data are limited.